Analysis on Characteristics of Antibacterial Use in Inpatients with Chronic Kidney Disease

Abstract

Abstract: Objective To investigate the use of antibacterials in patients with chronic kidney disease(CKD) and evaluate the drug safety for providing some clinical reference. Methods Inpatients with CKD over a 10-month period from January to October, 2014 in our hospital were analyzed retrospectively. Results In the 1 793 cases of hospitalized patients with CKD, the incidence of infection was 20.86%, mainly respiratory and urinary tract infections. 495 cases were treated with antibacterials, 345 cases for treating and 150 cases for preventing. In cases for treating, pathogenic bacteria were detected in 69.52% of the patients. Quinolones and cephalosporins were the most commonly used antibacterials. There were 66 cases with drug combinations, 22 cases with adverse drug reactions, and the adverse reactions of digestive system were the most common. Conclusion Inpatients with CKD are basically safe to use antibiotics. The dosage regimen should be adjusted by renal condition in the clinic.

Key words: chronic kidney disease, antibacterials, safety

CLC Number:

R969.3

CHEN Tianao, LIU Xiao, LIANG Yan. Analysis on Characteristics of Antibacterial Use in Inpatients with Chronic Kidney Disease[J]. Chinese Journal of Pharmacovigilance, 2018, 15(9): 550-554.

References

[1] 张佩嘉,谭洁.互联网技术用于慢性肾脏病健康管理的研究进展[J].护理学杂志,2017,32(1): 99-102.
[2] 胡双翼.肾内科住院患者抗菌药物应用特点的临床分析[J].世界最新医学信息文摘,2017,17(83):152,164.
[3] Kasiske B L, Wheeler D C.KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword[J]. Kidney International Supplements, 2013, 3(1):2.
[4] 国家卫生计生委.印发抗菌药物临床应用指导原则(2015年版)[J]. 中国医药生物技术, 2015,10(5):477.
[5] Go A S, Chertow G M, Fan D, et al.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization[J]. N Engl J Med, 2004,351(13):1296-1305.
[6] 樊佳,韩飞,王仁定,等. 慢性肾脏病患者发生医院感染的临床分析[J]. 中华医院感染学杂志, 2012,22(22):5015-5017.
[7] 李洁,朱潮涌,鲍晓红. 慢性肾脏疾病患者发生医院感染的特点与危险因素分析[J]. 中国现代医生, 2012,50(8):52-53.
[8] Yoon J W, Gollapudi S, Pahl M V, et al.Na ve and central memory T-cell lymphopenia in end-stage renal disease[J]. Kidney Int, 2006,70(2):371-376.
[9] 于敏,李澜,王姣,等. 狼疮性肾炎患者并发医院感染的临床特点及相关因素分析[J]. 中华医院感染学杂志, 2010,20(17):2594-2596.
[10] 潘文森,袁雅冬.慢性肾脏病合并感染的治疗[J].临床荟萃,2016,31(6):615-620.
[11] 郑茜子,苏涛,王玉,等. 氟喹诺酮类药物肾损害[J]. 中国实用内科杂志, 2011,31(3):229-231.
[12] 史浩,任红.慢性肾脏病患者抗菌药物的合理应用[J].世界临床药物,2013,34(11):704-707.
[13] Loghman-Adham M, Kiu W C I, Ciorciaro C, et al. Detection and management of nephrotoxicity during drug development[J]. Expert Opin Drug Saf, 2012,11(4):581-596.
[14] Khalili H, Bairami S, Kargar M.Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome[J]. Acta Med Iran, 2013,51(12):871-878.
[15] 赵靓,郭代红,朱曼,等.501例药源性肾损伤分析[J].中国药物警戒,2015,12(10):627-631.
[16] Choudhury D, Ahmed Z.Drug-associated renal dysfunction and injury[J]. Nat Clin Pract Nephrol, 2006,2(2):80-91.
[17] 刘可欣,管玫,严郁,等.抗菌药物的药源性肾损害[J].中国药师,2015,18(3):476-479.
[18] 徐世希. 药物性肾损伤29例临床分析[J].中国药业,2017,26(15):85-87.
[19] 曹菊, 苏涛, 李晓玫. 抗感染药物导致的急性肾损伤[J]. 药物不良反应杂志, 2010,12(5):325-328.
[20] Jr O R, Ambrose P G.Antimicrobial safety: focus on fluoroquino-lones[J]. Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America, 2005, 41(Suppl 2):144-157.
[21] 戴丽. 喹诺酮类药物临床应用及不良反应[J]. 中华医院感染学杂志, 2012,22(1):163-164.
[22] 蔺以 .氟喹诺酮类药物临床应用的不良反应与用药原则[J]. 中国医药科学, 2012,2(1):102-103,105.
[23] 谭莉莉. 喹诺酮类抗菌药物的临床不良反应[J].中国药物警戒,2013,10(2):92-95.
[24] 张莉蓉. 氟喹诺酮类抗菌药物不良反应的流行病学及中枢神经毒性研究[D] :复旦大学,2003.